Clinical Cardiology Alert – November 1, 2003
November 1, 2003
View Issues
-
Late-Breaking Trials from the European Society of Cardiology Congress in Vienna, Austria: CHARM
The 3 CHARM studies (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) and their combined results were presented at the ESC meeting and published in Lancet in September. -
Late-Breaking Trials from the European Society of Cardiology Congress: EUROPA
The European Trial of Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) study tested the hypothesis that perindopril in patients with stable coronary artery disease, but without heart failure or substantial hypertension, will reduce cardiovascular deaths, myocardial infarction, and cardiac arrest. -
Late-Breaking Trials from the European Society of Cardiology Congress: TAXUS IV
Drs. Gregg Stone and Stephen Ellis presented the 9-month clinical and angiographic results from TAXUS IV, which was designed to assess the safety and efficacy of the TAXUS slow-release polymer-based paclitaxel-eluting Express2 stent (Boston Scientific) in a broad cross-section of patients. -
Late-Breaking Trials from the European Society of Cardiology Congress: ISAR-COOL
The intracoronary stenting with antithrombotic Regimen Cooling Off (ISAR-COOL) study results were initially presented at the 2002 American Heart Association Scientific Session. -
Intensity of Anticoagulation in Atrial Fibrillation
Hylek and colleagues report on the effects of varying intensities of oral anticoagulation on the frequency and severity of strokes among patients with atrial fibrillation. -
Depressed Platelets
Sertraline contributed to a decrease in platelet activation over and above either aspirin or thienopyridines, and the SSRI might represent an attractive additional advantage for patients with depression and comorbid coronary artery disease and stroke. -
Clinical Briefs in Primary Care Supplement
Insulin Plus Metformin vs Triple Oral Therapy in Type 2 Diabetes; ARB and ACE-I in Diabetic Nephropathy; Low-Glycemic Index Diets and Diabetes; Ultralow-Dose Estrogen and Bone in Older Women; Effect of Intensity of Oral Anticoagulation in Atrial Fibrillation; Patient Knowledge and Awareness of Hypertension -
Pharmacology Watch: Generic Paxil Scheduled to Hit Market this Fall
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market. The drug marks the second SSRI antidepressant to go generic after fluoxetine (Prozac) last year.